Considerations For Using iPSCs In NK Cell Therapy Development

NKs are increasingly being explored as cell therapy treatments because of their promising safety and efficacy profile. However, autologous NK treatments also have limitations such as the extensive treatment regimen patients receive prior to NK cell collection and therapy, which can impair cell expansion and function after infusion.

Allogeneic NK therapies are able to leverage healthy donor cells as starting material, eliminating the risk of cells being poisoned by the chemotherapy that patients must undergo before autologous therapy. Explore how allogeneic therapies are poised to expand the potential of NKs to treat serious or life-threatening diseases and the challenges that still need addressed to facilitate adoption.